These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35757255)

  • 1. Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management.
    Nurcahyanti ADR; Cokro F; Wulanjati MP; Mahmoud MF; Wink M; Sobeh M
    Front Nutr; 2022; 9():891339. PubMed ID: 35757255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical markers' knockout coupled with UHPLC-HRMS-based metabolomics reveals anti-cancer integration effects of the curcuminoids of turmeric (Curcuma longa L.) on lung cancer cell line.
    Zhou JL; Zheng JY; Cheng XQ; Xin GZ; Wang SL; Xie T
    J Pharm Biomed Anal; 2019 Oct; 175():112738. PubMed ID: 31362249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis.
    Panahi Y; Hosseini MS; Khalili N; Naimi E; Majeed M; Sahebkar A
    Clin Nutr; 2015 Dec; 34(6):1101-8. PubMed ID: 25618800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
    Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A
    Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of turmeric (Curcuma longa) and its constituent (curcumin) on the metabolic syndrome: An updated review.
    Vafaeipour Z; Razavi BM; Hosseinzadeh H
    J Integr Med; 2022 May; 20(3):193-203. PubMed ID: 35292209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: Systematic review and meta-analysis of randomized controlled trials.
    de Melo ISV; Dos Santos AF; Bueno NB
    Pharmacol Res; 2018 Feb; 128():137-144. PubMed ID: 28928074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.
    Korczak D; Dietl M; Steinhauser G
    GMS Health Technol Assess; 2011 Apr; 7():Doc02. PubMed ID: 21468290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial.
    Panahi Y; Khalili N; Hosseini MS; Abbasinazari M; Sahebkar A
    Complement Ther Med; 2014 Oct; 22(5):851-7. PubMed ID: 25440375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of turmeric in Alzheimer's disease: curcumin or curcuminoids?
    Ahmed T; Gilani AH
    Phytother Res; 2014 Apr; 28(4):517-25. PubMed ID: 23873854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
    Musso G; Cassader M; Rosina F; Gambino R
    Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Chashmniam S; Mirhafez SR; Dehabeh M; Hariri M; Azimi Nezhad M; Nobakht M Gh BF
    Eur J Clin Nutr; 2019 Sep; 73(9):1224-1235. PubMed ID: 30647436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro and in vivo study of a 4-herb formula on the management of diet-induced metabolic syndrome.
    Wat E; Wang Y; Chan K; Law HW; Koon CM; Lau KM; Leung PC; Yan C; Lau CBS
    Phytomedicine; 2018 Mar; 42():112-125. PubMed ID: 29655677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.
    Baziar N; Parohan M
    Phytother Res; 2020 Mar; 34(3):464-474. PubMed ID: 31799714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcuminoid Demethylation as an Alternative Metabolism by Human Intestinal Microbiota.
    Burapan S; Kim M; Han J
    J Agric Food Chem; 2017 Apr; 65(16):3305-3310. PubMed ID: 28401758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Formulation of Curcuminoids on Their Metabolism by Human Colonic Microbiota.
    Bresciani L; Favari C; Calani L; Francinelli V; Riva A; Petrangolini G; Allegrini P; Mena P; Del Rio D
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32093121
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.